News

1 2 3 4 5 10 14 18
NEWS

SOTIO Announces Clinical Collaboration with MSD to evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

  • The Phase 2 AURELIO-04 study is expected to enroll up to 300 patients across six different indications
  • The study will be conducted in the US and selected European countries and will begin in the first half of 2022

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., through its subsidiaries, to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® (pembrolizumab) in patients with selected advanced/refractory solid tumors in the phase 2 AURELIO-04 study.

NEWS

SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline

  • PPF Group provides funding to advance SOTIO through key clinical milestones
  • Proceeds shall be used to conduct two phase 2 studies with SOT101, including a checkpoint inhibitor combination trial
  • Three programs (SOT102, BOXR1030, and SOT201) to advance through phase 1

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that is has secured €280m of funding to significantly expand and advance its clinical pipeline, including its lead asset SOT101, an IL-15 superagonist, and three new clinical programs until end of 2023.

NEWS

SOTIO Strengthens its Strategic Advisory Board with Esteemed Oncology Experts and Industry Veterans

SOTIO Biotech, a clinical stage immune-oncology company owned by PPF Group, announced the addition of three world-renowned clinical oncology research experts and biotechnology business development and commercialization veterans to its strategic advisory board. New members of the Strategic Advisory Board include Alise Reicin, M.D., Josep Tabernero, M.D., Ph.D. and Anthony Tolcher, M.D., FRCPS(C).